Targeting Improved Outcomes for Colorectal Cancer After Surgery and Treatment
NCT07227636 · RecruitingThis study looks at whether using botensilimab and balstilimab together, followed by balstilimab alone, helps people with certain types of colorectal cancer. The focus is on those who have some cancer left after surgery and chemotherapy. Researchers want to see how well this combination works for patients with microsatellite stable colorectal cancer or liver metastases after standard treatments.
Locations and contact
This trial is running at 7 locations in the United States. All of them are currently recruiting.
United States7 locations · 7 recruiting
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, New JerseyRecruiting
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, New JerseyRecruiting
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New YorkRecruiting
- Memorial Sloan Kettering Commack (Limited Protocol Activities)Commack, New YorkRecruiting
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, New JerseyRecruiting
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre, New YorkRecruiting
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New YorkRecruiting
Who can join
Adults aged 18 and older can join the trial. It is open to both men and women. Participants must have confirmed colorectal cancer and must have had surgery and chemotherapy. People with certain health conditions or treatments in the past few weeks may not be eligible. The trial team will confirm who can take part.
What happens during the trial
Participants will be placed into different groups by chance. Everyone in the first two groups will receive the combination of botensilimab and balstilimab. After that, they will continue with balstilimab alone for additional cycles. In the last two groups, participants will receive either the combination of the two medicines or a placebo, which is a substance without active medicine. This is done to compare the effects of the treatments.
The trial team
The trial is sponsored by Memorial Sloan Kettering Cancer Center. Dr. Neil Segal is the principal investigator leading the study. Agenus Inc. is collaborating on this research.
Important dates
The trial started on November 7, 2025, and is expected to finish by November 2030. It is currently enrolling new participants.
Additional information
The trial ID is NCT07227636. This is a Phase 2 study, which means it is looking at how well the treatment works and how safe it is. It is regulated by the FDA and aims to include about 284 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →